NeuroVision Imaging Inc. today announced the acquisition of Durin Life Sciences Inc., creating an integrated neurodegenerative disease diagnostics and care platform focused on advancing earlier detection, patient access, and longitudinal brain health management.

NeuroVision Imaging Inc. 今天宣布收购 Durin Life Sciences Inc.，创建了一个专注于推进早期检测、患者获取和纵向大脑健康管理的神经退行性疾病诊断和护理平台。

The transaction combines Durin’s blood-based biomarker diagnostics platform with NeuroVision’s retinal imaging technology, telehealth infrastructure, and BrainHealth.net patient engagement platform. The combined company will operate under the NeuroVision name and continue to be led by Steven Verdooner, CEO and co-founder of NeuroVision..

该交易将Durin的基于血液的生物标志物诊断平台与NeuroVision的视网膜成像技术、远程医疗基础设施和BrainHealth.net患者互动平台相结合。合并后的公司将以NeuroVision的名义运营，并继续由NeuroVision的首席执行官兼联合创始人史蒂文·维尔杜纳领导。

Together, the companies aim to accelerate the development and commercialization of innovative diagnostic solutions for Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and related neurological disorders by pairing advanced biomarker science with scalable clinical, data, and patient engagement capabilities..

这些公司共同致力于通过将先进的生物标志物科学与可扩展的临床、数据和患者参与能力相结合，加速阿尔茨海默病、帕金森病、肌萎缩侧索硬化症 (ALS) 以及相关神经系统疾病的创新诊断解决方案的开发和商业化。

Durin Life Sciences developed Duritect™, a suite of blood-based diagnostic tests designed to support the early detection and monitoring of neurodegenerative disease. NeuroVision contributes its established BrainHealth.net platform, which supports patients, providers, and healthcare organizations across the United States through telehealth-enabled cognitive assessment, care navigation, and longitudinal brain health programs..

Durin生命科学公司开发了Duritect™，这是一套基于血液的诊断测试，旨在支持神经退行性疾病的早期检测和监测。NeuroVision提供了其成熟的BrainHealth.net平台，该平台通过远程医疗赋能的认知评估、护理导航和长期脑健康计划，为全美国的患者、医疗服务提供者和医疗机构提供支持。

“We’ve long believed that the future of neurodegenerative disease care begins with earlier and more accessible detection,” said Verdooner. “Durin’s blood-based biomarker platform represents an important advancement in that direction. By bringing together complementary strengths in diagnostics, technology and patient engagement, we believe we are uniquely positioned to help advance brain health at scale while supporting patients and families throughout the care journey.”.

“我们一直认为，神经退行性疾病护理的未来始于更早和更便捷的检测，”Verdooner说道。“Durin的基于血液的生物标志物平台代表了在这一方向上的重要进步。通过整合诊断、技术和患者参与方面的互补优势，我们相信自己能够以规模化的方式推动脑健康的发展，同时在整个护理过程中为患者及其家庭提供支持。”

Ric Edelman, majority owner of Durin, is joining the board of the combined enterprise. He said, “This is a milestone for Durin and for everyone who has been part of our journey, and we're excited to be joining forces with NeuroVision.”

里克·埃德尔曼，杜兰公司的多数股东，将加入合并后的企业董事会。他表示：“这是杜兰公司以及所有参与我们旅程的人的一个里程碑，我们很高兴能与NeuroVision携手合作。”

About NeuroVision Imaging

关于NeuroVision成像

NeuroVision Imaging Inc., founded in 2010 and headquartered in Sacramento, is a healthcare technology company focused on improving neurological outcomes through earlier detection, patient engagement, and scalable brain health programs. Through its BrainHealth.net platform and retinal imaging technologies, NeuroVision provides diagnostic support, care navigation, and longitudinal lifestyle intervention programs for patients at risk for neurodegenerative disease.

NeuroVision Imaging Inc. 成立于2010年，总部位于萨克拉门托，是一家专注于通过早期检测、患者参与和可扩展的脑健康项目来改善神经学结果的医疗技术公司。通过其BrainHealth.net平台和视网膜成像技术，NeuroVision为有神经退行性疾病风险的患者提供诊断支持、护理导航和长期生活方式干预项目。

The company collaborates with healthcare systems, academic institutions, and industry partners to advance innovation in neurological care. Learn more at NeuroVision Imaging..

该公司与医疗系统、学术机构和行业伙伴合作，推动神经护理领域的创新。欲了解更多信息，请访问NeuroVision Imaging。

About Durin Life Sciences

关于杜林生命科学

Durin Life Sciences Inc. develops noninvasive, accessible diagnostic tests for some of the most prevalent and devastating neurodegenerative disorders, including Alzheimer’s, Parkinson’s disease, and ALS. Its rapid-result Duritect™ diagnostic tests are designed to enable earlier detection and monitoring of disease progression, in some cases, years before symptoms appear.

德林生命科学公司开发了针对一些最普遍和破坏性最强的神经退行性疾病（包括阿尔茨海默病、帕金森病和肌萎缩侧索硬化症）的无创、易获取的诊断测试。其快速结果的Duritect™诊断测试旨在实现更早地检测和监测疾病进展，在某些情况下，甚至在症状出现前几年即可做到。

The company’s scientific platform is designed to support a broad pipeline of future diagnostic applications beyond neurodegenerative disease..

该公司的科学平台旨在支持广泛的未来诊断应用，超越神经退行性疾病。

Contacts

联系人

Media Contact:

媒体联系人:

Sandy Van

桑迪·范

sandy@prpacific.com

sandy@prpacific.com

808.206.4576

808.206.4576

Source: businesswire.com

来源：businesswire.com